Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Cytokine1 who wrote (7521)	1/31/2000 9:37:00 AM
From: Don Miller	Respond to of 9719

How serious is this for SEPR? "CCR3 Antagonism by the B-chemokine MIP-4, a property strongly enhanced by an amino-terminal alanine-methionine swap" and is published in the February 1, 2000 issue of the Journal of Immunology. This paper may be accessed at jimmunol.org. quicken.com Advance in Asthma Research Announced Monday, January 31, 2000 08:01 AM Human Genome Sciences and Scottish Researchers Discover New Substance That Blocks Allergic Reactions May Have Potential to Treat Asthma and Allergic Diseases ROCKVILLE, Md. and GLASGOW, Scotland, Jan. 31 /PRNewswire/ -- A team of scientists working at Human Genome Sciences, Inc. (Nasdaq: HGSI, news, msgs), in Rockville, Maryland, and the CRC Beatson Institute for Cancer Research, in Glasgow, Scotland, announced today the discovery of a new protein that blocks a key receptor on a type of cell that induces allergic reactions. The protein is called Met-Chemokine Beta Seven, or Met-CkB7. The discovery of this protein is described in a paper published in the February 1, 2000 issue of the Journal of Immunology. Met-Chemokine Beta Seven interferes with the function of a cell type, called an eosinophil, that plays a central role in asthma and allergic reactions. During allergic reactions, eosinophils migrate to the lungs and trigger many of the symptoms of asthma and allergy. The newly discovered protein blocks eosinophil migration by binding to a structure on the surface of the cells. Once blocked, the ability of eosinophils to induce asthma and allergic symptoms is greatly reduced.

To: Cytokine1 who wrote (7521)	1/31/2000 9:12:00 PM
From: Cytokine1	Read Replies (1) \| Respond to of 9719

VD's MODEL PORTFOLIO 1/31/00 Change -$21203 DOWN -2.10% Started 4/9/97, $100K . INDEX ^IXB UP 2.02% YTD EQUITY CHANGE 33.8% # CURRENT DAILY CURRENT COST TOTAL %GAIN/ % OF SYMBOL SHRS PRICE CHANGE %CHG VALUE SHR COST LOSS TOTAL ======= ======= ======= ======= ======= ======= ======= ======= ======= ======= NBIX 1000 23.75 -0.75 -3.06% 23750 6.00 6000 295.8% 2.4% INCY 1000 109.75 -18.75 -14.59% 109750 28.95 28954 279.0% 11.1% ABSC 1500 36.50 0.59 1.65% 54750 8.761 13141 316.6% 5.6% BTRN 3000 7.63 0.38 5.17% 22875 2.25 6750 238.9% 2.3% NPSP 2000 13.75 -0.88 -5.98% 27500 5.50 11000 150.0% 2.8% CELG 2000 69.75 -3.50 -4.78% 139500 27.10 54200 157.4% 14.1% CGPI 2000 24.25 -0.50 -2.02% 48500 9.00 18000 169.4% 4.9% GZTC 2000 15.50 -0.50 -3.13% 31000 7.737 15475 100.3% 3.1% MOGN 1500 20.25 -0.50 -2.41% 30375 8.667 13000 133.7% 3.1% TRMS 3000 52.88 4.38 9.02% 158625 21.77 65313 142.9% 16.1% SEPR 1000 140.00 2.75 2.00% 140000 84.71 84713 65.3% 14.2% CLTR 5500 23.38 -0.50 -2.09% 128563 16.76 92156 39.5% 13.0% EPPH.OB 3000 6.19 -0.25 -3.88% 18563 6.25 18750 -1.0% 1.9% GLIA 3500 15.06 -1.31 -8.02% 52719 17.5625 61469 -14.2% 5.3% STOCK ______ ______ ______ ______ 986469 488920 101.8% 100.0% SHORT SALE CREDIT ______ ______ 0 MARGIN MTCE. EQUITY 85.1% MIN 30% (147219) BUYING POWER $ ______ 692031 EQUITY (NAV) ______ ______ ______ 839250 100000 739.2% ^IXB INDEX 1,015.78 20.11 2.02% 302.42 235.9% NOTES: OPEN orders subject to available buying power--- BUY 500 NBIX @ $20 . BUY 500 SEPR @ $90 . BUY 500 SEPR @ $95 . . . 01/11/1999 -16000 BUY 1000 GLIA @ $16.00 01/11/2000 -18750 BUY 3000 EPPH.OB @ $6.25 01/07/2000 -30000 BUY 500 CELG @ $60.00 01/04/2000 -20712.5 BUY 200 SEPR @ $103.5625